HPV and oropharyngeal cancer: Etiology and prognostic importance

Seminars in Cutaneous Medicine and Surgery

Volumn 34, Issue 4, 2015, Pages 178-181

  Yom, Sue S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; CETUXIMAB; CISPLATIN; PACLITAXEL; PLATINUM COMPLEX; PROTEIN P16; VIRUS DNA;

ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER TISSUE; CHEMORADIOTHERAPY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG DOSE INTENSIFICATION; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOHISTOCHEMISTRY; INDUCTION CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OROPHARYNX CANCER; OVERALL SURVIVAL; PAPILLOMAVIRUS INFECTION; QUALITY OF LIFE; WART VIRUS; DIFFERENTIAL DIAGNOSIS; GENETICS; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PROGNOSIS; VIROLOGY;

DIAGNOSIS, DIFFERENTIAL; DNA, VIRAL; HUMANS; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PROGNOSIS;

EID: 84958244078     PISSN: 10855629     EISSN: 15580768     Source Type: Journal    
DOI: 10.12788/j.sder.2015.0182     Document Type: Article

References (36)

1. Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41(11)660-664.
2. Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA. 2012;307(7):693-703.
3. Beachler DC, Guo Y, Xiao W, et al. High oral human papillomavirus type 16 load predicts long-term persistence in individuals with or at risk for HIV infection [published online ahead of print May 7, 2015]. J Infect Dis. Pii:jiv273.
4. Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013;73(6):1733-1741.
5. Rositch AF, Burke AE, Viscidi RP, Silver MI, Chang K, Gravitt PE. Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women. Cancer Res. 2012;72(23):6183-6190.
6. Chaturvedi AK, Graubard BI, Broutian T, et al. NHANES 2009-2012 findings: association of sexual behaviors with higher prevalence of oral oncogenic human papillomavirus infections in U.S. men. Cancer Res. 2015;75 (12):2468-2477.
7. Paz IB, Cook N, Odom-Maryon T, Xie Y, Wilczynski SP. Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring. Cancer. 1997;79(3):595-604.
8. Wilczynski SP, Lin BT, Xie Y, Paz IB. Detection of human papillomavirus DNA and oncoprotein overexpression are associated with distinct morphological patterns of tonsillar squamous cell carcinoma. Am J Pathol. 1998;152(1):145-156
9. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92(9):709-720.
10. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294-4301.
11. Mork J, Lie AK, Glattre E, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med. 2001;344(15):1125-1131.
12. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14(2):467-475.
13. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and-unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008;26(4):612-619.
14. Saraiya M, Unger ER, Thompson TD, et al; HPV Typing of Cancers Workgroup. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. 2015;107(6):djv086.
15. Gillison ML, D'Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008;100(6):407-420.
16. Benson E, Li R, Eisele D, Fakhry C. The clinical impact of HPV tumor status upon head and neck squamous cell carcinomas. Oral Oncol. 2014;50(6):565-574.
17. McIlwain WR, Sood AJ, Nguyen SA, Day TA. Initial symptoms in patients with HPV-positive and HPV-negative oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg. 2014;140(5):441-447.
18. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24-35.
19. Lewis JS, Jr. p16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma. Head Neck Pathol. 2012;6(Suppl 1):S75-S82.
20. Westra WH. Detection of human papillomavirus (HPV) in clinical samples: evolving methods and strategies for the accurate determination of HPV status of head and neck carcinomas. Oral Oncol. 2014;50(9):771-779.
21. Shi W, Kato H, Perez-Ordonez B, et al. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol. 2009;27(36):6213-6221.
22. Bourhis J, Sire C, Graff P, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol. 2012;13(2):145-153.
23. Trotti A, Pajak TF, Gwede CK, et al. TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol. 2007;8(7):613-624.
24. Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008;26(21):3582-3589.
25. O'Sullivan B, Huang SH, Siu LL, et al. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol. 2013;31(5):543-550.
26. Cmelak A, Li S, Marur S, et al. E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC). J Clin Oncol. 2014;32(5s).
27. Eastern Cooperative Oncology Group. Paclitaxel, Cisplatin, and Cetuximab Followed By Cetuximab and Intensity-Modulated Radiation Therapy in Treating Patients With HPV-Associated Stage III or Stage IV Cancer of the Oropharynx That Can Be Removed By Surgery. In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 October 27. Available from: https://clinicaltrials. gov/ct2/show/NCT01084083?term=NCT01084083&rank=1. NLM Identifier: NCT01084083.
28. Icahn School of Medicine at Mount Sinai. The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer. In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 October 27. Available from: https://clinicaltrials.gov/ct2/show/NCT01706939?term=NCT01706939&rank=1. NLM Identifier: NCT01706939.
29. Radiation Therapy Oncology Group. Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 October 27. Available from: .https://clinicaltrials.gov/ct2/show/NCT01302834?term=NCT0130 2834&rank=1. NLM Identifier: NCT01302834.
30. Trans-Tasman Radiation Oncology Group (TROG). Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPVOropharynx). In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 October 27. Available from: https://clinicaltrials. gov/ct2/show/NCT01855451?term=NCT01855451&rank=1. NLM Identifier: NCT01855451.
31. University of Warwick. Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC (De-ESCALaTE). In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 October 27. Available from: https://clinicaltrials.gov/ct2/show/NCT01874171?term=NCT0187 4171&rank=1. NLM Identifier: NCT01874171.
32. National Cancer Institute. Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer. In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 October 27. Available from: https://clinicaltrials.gov/ct2/show/NCT022 54278?term=NCT02254278&rank=1. NLM Identifier: NCT02254278.
33. de Almeida JR, Li R, Magnuson JS, et al. Oncologic outcomes after transoral robotic surgery: a multi-institutional study. JAMA Otolaryngol Head Neck Surg. 2015:1-9.
34. Eastern Cooperative Oncology Group. Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 October 27. Available from: https://clinicaltrials.gov/ct2/show/NCT01898494. NLM Identifier: NCT01898494.
35. Washington University School of Medicine. Post Operative Adjuvant Therapy Deintensification Trial for Human Papillomavirus-related, p16+ Oropharynx Cancer (ADEPT). In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 October 27. Available from: https://clinicaltrials.gov/ct2/show/NCT01687413?term=NCT01687413&rank=1. NLM Identifier: NCT01687413.
36. Lawson Health Research Institute. A Phase II Randomized Trial for Early-stage Squamous Cell Carcinoma of the Oropharynx: Radiotherapy vs Trans-oral Robotic Surgery (ORATOR). In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 October 27. Available from: https://clinicaltrials. gov/ct2/show/NCT01590355?term=NCT01590355&rank=1. NLM Identifier: NCT01590355.